Recombinant interleukin-2 therapy for angiosarcoma of the breast; Efficacy of daily or weekly administration:A case report
スポンサーリンク
概要
- 論文の詳細を見る
We report the first case of recombinant interleukin-2 (rIL-2) therapy for breast angiosarcoma after mastectomy. We evaluated the changes of killing activity in peripheral blood mononuclear cells (PBMC) by the 51Cr-release assay. Daily intravenous administration of rIL-2 increased the natural killer (NK) cell population and enhanced cytotoxicity. After the cessation of daily rIL-2 administration for 4 weeks, the enhanced cytotoxicity was not maintained by weekly administration of rIL-2. Months after mastectomy, local and distal metastases were observed, despite this immunotherapy. These results suggest that immunotherapy with rIL-2 is insufficient treatment for breast angiosarcoma, and that other modalities such as chemotherapy should be taken in consideration for use in combination with immunotherapy.
- 日本癌病態治療研究会の論文
日本癌病態治療研究会 | 論文
- Current status of tumor necrosis factor-related apoptosis-inducing ligand receptor (TRAIL-R) targeting cancer therapy
- Endoscopic Mucosal Resection (EMR) for Colorectal Lesions and Lesion-lifted Condition as an Indicator of the Tumor Invasion
- NOVEL APPROACH TO IMMUNOTHERAPY FOR EPITHELIAL CANCERS, BONE AND SOFT-TISSUE SARCOMAS
- Extracellular heat shock proteins (eHSPs) pilot exogenous antigen into cross-presentation pathway: A superguide from extracellular world to intracellular tour
- Preoperative body mass index and outcomes of gastric cancer patients